Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $94.60 Consensus PT from Analysts
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have received an average rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in […]
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have received an average rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in […]
